PubMed:32471903 / 1090-1336 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T14","span":{"begin":38,"end":56},"obj":"CHEBI:35842"},{"id":"T15","span":{"begin":38,"end":56},"obj":"CHEBI:35842"},{"id":"T16","span":{"begin":117,"end":127},"obj":"CHEBI:66921"},{"id":"T17","span":{"begin":117,"end":127},"obj":"CHEBI:66921"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively)."}

{"project":"Inflammaging","denotations":[{"id":"T13","span":{"begin":0,"end":246},"obj":"Sentence"},{"id":"T13","span":{"begin":0,"end":246},"obj":"Sentence"}],"text":"Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively)."}